31 related articles for article (PubMed ID: 7517668)
1. Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
Das K; Bauman JD; Rim AS; Dharia C; Clark AD; Camarasa MJ; Balzarini J; Arnold E
J Med Chem; 2011 Apr; 54(8):2727-37. PubMed ID: 21446702
[TBL] [Abstract][Full Text] [Related]
2. Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.
Xu HT; Colby-Germinario SP; Asahchop EL; Oliveira M; McCallum M; Schader SM; Han Y; Quan Y; Sarafianos SG; Wainberg MA
Antimicrob Agents Chemother; 2013 Jul; 57(7):3100-9. PubMed ID: 23612196
[TBL] [Abstract][Full Text] [Related]
3. Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase.
Xu HT; Oliveira M; Quashie PK; McCallum M; Han Y; Quan Y; Brenner BG; Wainberg MA
J Virol; 2012 Aug; 86(16):8422-31. PubMed ID: 22623801
[TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors.
Balzarini J; Karlsson A; Vandamme AM; Pérez-Pérez MJ; Zhang H; Vrang L; Oberg B; Bäckbro K; Unge T; San-Félix A
Proc Natl Acad Sci U S A; 1993 Aug; 90(15):6952-6. PubMed ID: 7688467
[TBL] [Abstract][Full Text] [Related]
5. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.
Pelemans H; Aertsen A; Van Laethem K; Vandamme AM; De Clercq E; Pérez-Pérez MJ; San-Félix A; Velázquez S; Camarasa MJ; Balzarini J
Virology; 2001 Feb; 280(1):97-106. PubMed ID: 11162823
[TBL] [Abstract][Full Text] [Related]
6. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.
Balzarini J; Karlsson A; Pérez-Pérez MJ; Camarasa MJ; Tarpley WG; De Clercq E
J Virol; 1993 Sep; 67(9):5353-9. PubMed ID: 7688822
[TBL] [Abstract][Full Text] [Related]
7. Resistance of HIV-1 reverse transcriptase against [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2''-dioxide)] (TSAO) derivatives is determined by the mutation Glu138-->Lys on the p51 subunit.
Jonckheere H; Taymans JM; Balzarini J; Velázquez S; Camarasa MJ; Desmyter J; De Clercq E; Anné J
J Biol Chem; 1994 Oct; 269(41):25255-8. PubMed ID: 7523383
[TBL] [Abstract][Full Text] [Related]
8. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants.
Balzarini J; Karlsson A; Sardana VV; Emini EA; Camarasa MJ; De Clercq E
Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6599-603. PubMed ID: 7517553
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of (138 Glu-->Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors.
Balzarini J; Kleim JP; Riess G; Camarasa MJ; De Clercq E; Karlsson A
Biochem Biophys Res Commun; 1994 Jun; 201(3):1305-12. PubMed ID: 7517668
[TBL] [Abstract][Full Text] [Related]
10. [Highly specific inhibitors of human immunodeficiency virus type I that are particularly targeted at the reverse transcriptase].
de Clercq E; Snoeck R
Pathol Biol (Paris); 1993 Mar; 41(3):230-6. PubMed ID: 7687340
[No Abstract] [Full Text] [Related]
11. HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase.
De Clercq E
Med Res Rev; 1993 May; 13(3):229-58. PubMed ID: 7683360
[TBL] [Abstract][Full Text] [Related]
12. The genetic and functional basis of HIV-1 resistance to nonnucleoside reverse transcriptase inhibitors.
Emini EA; Byrnes VW; Condra JH; Schleif WA; Sardana VV
Arch Virol Suppl; 1994; 9():11-7. PubMed ID: 7518271
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
